Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Auteurs : Berghmans T, Paesmans M, Sculier JP
Jaar : 2011
Journal : Ther Adv Med Oncol
Volume : 3(3)
Pagina's : 127-38

Positron emission tomography with 18F-FDG and cancer response to chemotherapy].

Auteurs : van Ruychevelt V, Garcia C, Meert AP, Berghmans T, Paesmans M, Flamen P, Sculier JP
Jaar : 2011
Journal : Rev Mal Respir
Volume : 28(5)
Pagina's : 618-25

Validation and comparison of several published prognostic systems for patients with small cell lung cancer.

Auteurs : Paesmans M, Lafitte JJ, Lecomte J, Berghmans T, Efremidis A, Giner V, Van Cutsem O, Scherpereel A, Meert AP, Leclercq N, Van Houtte P, Sculier JP
Jaar : 2011
Journal : Eur. Respir. J.
Volume : 38(3)
Pagina's : 657-63

Febrile neutropenia: a critical review of the initial management.

Auteurs : Klastersky J, Awada A, Paesmans M, Aoun M
Jaar : 2011
Journal : Crit Rev Oncol Hematol
Volume : 78(3)
Pagina's : 185-94

Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?

Auteurs : Paesmans M, Klastersky J, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Ameye L
Jaar : 2011
Journal : Support Care Cancer
Volume : 19(7)
Pagina's : 1001-8

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.

Auteurs : Scherpereel A, Berghmans T, Lafitte JJ, Colinet B, Richez M, Bonduelle Y, Meert AP, Dhalluin X, Leclercq N, Paesmans M, Willems L, Sculier JP
Jaar : 2011
Journal : Eur. Respir. J.
Volume : 37(1)
Pagina's : 129-136

Treatment of febrile neutropenia is expensive: prevention is the answer.

Auteurs : Klastersky J, Paesmans M
Jaar : 2011
Journal : Onkologie
Volume : 34(5)
Pagina's : 226-8